he Seattle biotech Omeros (OMER) has reported sharply lower sales of its cataract surgery drug in the fourth quarter after losing favorable Medicare reimbursement at the end of last year.

Lacking a reimbursement fix, Omeros offered a bleak sales outlook for this year for the drug, Omidria, raising the risk that the company might end up in default on a business loan.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy